Literature DB >> 18791272

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.

Nicole Zache1, Jeremy M R Lambert, Klas G Wiman, Vladimir J N Bykov.   

Abstract

Reactivation of the tumor suppressor activity to mutant p53 should trigger massive apoptosis and eliminate tumors. The low molecular weight compounds PRIMA-1 and the structural analog PRIMA-1MET reactivate human mutant p53 in vitro and suppress growth of human tumor xenografts in SCID mice. However, little is known about their effect on mouse mutant p53 in mouse tumor cells. We have examined the effect of PRIMA-1MET on mouse sarcomas, mammary carcinomas and chemically induced fibrosarcomas. PRIMA-1MET showed potent growth suppression in mutant p53-carrying mouse tumors in vitro and a significant anti-tumor effect in syngeneic mice in vivo. These results demonstrate that PRIMA-1MET targets mouse tumors carrying mutant p53 and provide strong support for the anti-tumor efficiency of PRIMA-1MET in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791272      PMCID: PMC4618963          DOI: 10.3233/clo-2008-0440

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  33 in total

1.  Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.

Authors:  Joel L Kaar; Nicolas Basse; Andreas C Joerger; Elaine Stephens; Trevor J Rutherford; Alan R Fersht
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

Review 2.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

3.  Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.

Authors:  Jianmin Xu; Laura Timares; Clay Heilpern; Zhiping Weng; Changzhao Li; Hui Xu; Joseph G Pressey; Craig A Elmets; Levy Kopelovich; Mohammad Athar
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

Review 4.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

Review 5.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 6.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 7.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

8.  PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells.

Authors:  Chayanit Piyawajanusorn; Yingpinyapat Kittirat; Prakasit Sa-Ngiamwibool; Attapol Titapun; Watcharin Loilome; Nisana Namwat
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

9.  Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides.

Authors:  Célia Floquet; Jules Deforges; Jean-Pierre Rousset; Laure Bidou
Journal:  Nucleic Acids Res       Date:  2010-12-10       Impact factor: 16.971

10.  Markov state models and NMR uncover an overlooked allosteric loop in p53.

Authors:  Emilia P Barros; Özlem Demir; Jenaro Soto; Melanie J Cocco; Rommie E Amaro
Journal:  Chem Sci       Date:  2020-12-16       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.